Next Article in Journal
Pleiotropic Roles of Non-Coding RNAs in TGF-β-Mediated Epithelial-Mesenchymal Transition and Their Functions in Tumor Progression
Next Article in Special Issue
The Role of miRNAs in Angiogenesis, Invasion and Metabolism and Their Therapeutic Implications in Gliomas
Previous Article in Journal
Quality-of-Life (QOL) during Screening for Phase 1 Trial Studies in Patients with Advanced Solid Tumors and Its Impact on Risk for Serious Adverse Events
Previous Article in Special Issue
Exosomal MicroRNAs in Breast Cancer towards Diagnostic and Therapeutic Applications

Specific Depletion of Leukemic Stem Cells: Can MicroRNAs Make the Difference?

Department of Hematology, VU University Medical Center, Cancer Center Amsterdam, Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editors: Ryou-u Takahashi and Takahiro Ochiya
Cancers 2017, 9(7), 74;
Received: 2 May 2017 / Revised: 15 June 2017 / Accepted: 20 June 2017 / Published: 30 June 2017
For over 40 years the standard treatment for acute myeloid leukemia (AML) patients has been a combination of chemotherapy consisting of cytarabine and an anthracycline such as daunorubicin. This standard treatment results in complete remission (CR) in the majority of AML patients. However, despite these high CR rates, only 30–40% (<60 years) and 10–20% (>60 years) of patients survive five years after diagnosis. The main cause of this treatment failure is insufficient eradication of a subpopulation of chemotherapy resistant leukemic cells with stem cell-like properties, often referred to as “leukemic stem cells” (LSCs). LSCs co-exist in the bone marrow of the AML patient with residual healthy hematopoietic stem cells (HSCs), which are needed to reconstitute the blood after therapy. To prevent relapse, development of additional therapies targeting LSCs, while sparing HSCs, is essential. As LSCs are rare, heterogeneous and dynamic, these cells are extremely difficult to target by single gene therapies. Modulation of miRNAs and consequently the regulation of hundreds of their targets may be the key to successful elimination of resistant LSCs, either by inducing apoptosis or by sensitizing them for chemotherapy. To address the need for specific targeting of LSCs, miRNA expression patterns in highly enriched HSCs, LSCs, and leukemic progenitors, all derived from the same patients’ bone marrow, were determined and differentially expressed miRNAs between LSCs and HSCs and between LSCs and leukemic progenitors were identified. Several of these miRNAs are specifically expressed in LSCs and/or HSCs and associated with AML prognosis and treatment outcome. In this review, we will focus on the expression and function of miRNAs expressed in normal and leukemic stem cells that are residing within the AML bone marrow. Moreover, we will review their possible prospective as specific targets for anti-LSC therapy. View Full-Text
Keywords: MicroRNAs; AML; leukemic stem cells; hematopoietic stem cells MicroRNAs; AML; leukemic stem cells; hematopoietic stem cells
Show Figures

Figure 1

MDPI and ACS Style

Martiáñez Canales, T.; De Leeuw, D.C.; Vermue, E.; Ossenkoppele, G.J.; Smit, L. Specific Depletion of Leukemic Stem Cells: Can MicroRNAs Make the Difference? Cancers 2017, 9, 74.

AMA Style

Martiáñez Canales T, De Leeuw DC, Vermue E, Ossenkoppele GJ, Smit L. Specific Depletion of Leukemic Stem Cells: Can MicroRNAs Make the Difference? Cancers. 2017; 9(7):74.

Chicago/Turabian Style

Martiáñez Canales, Tania, David C. De Leeuw, Eline Vermue, Gert J. Ossenkoppele, and Linda Smit. 2017. "Specific Depletion of Leukemic Stem Cells: Can MicroRNAs Make the Difference?" Cancers 9, no. 7: 74.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop